"10.1371_journal.pone.0135520","plos one","2015-08-21T00:00:00Z","Eric Laille; Tao Shi; Guillermo Garcia-Manero; Christopher R Cogle; Steven D Gore; Joel Hetzer; Keshava Kumar; Barry Skikne; Kyle J MacBeth","Celgene Corporation, Summit, New Jersey, United States of America; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, United States of America; Division of Hematology/Oncology, University of Florida, Gainesville, Florida, United States of America; Yale Cancer Center, New Haven, Connecticut, United States of America","Conceived and designed the experiments: EL GG-M CRC SDG KK BS KJM. Performed the experiments: EL TS KK KJM. Analyzed the data: EL TS JH KJM. Contributed reagents/materials/analysis tools: EL TS GG-M CRC SDG KK KJM. Wrote the paper: EL TS GG-M CRC SDG JH KK BS KJM.","EL, TS, JH, KK, BS, and KM are employed by Celgene Corporation and own Celgene stock. GG-M has received research support from Celgene Corp, and is a consultant and speaker for Celgene. SDG receives research support from and consults for the Celgene Corporation. CRC serves on the Scientific Advisory Board for the Connect MDS/AML Disease Registry study, which is sponsored by Celgene. This study was funded by Celgene Corporation. Sheila Truten and Brian Kaiser of MC2 provided editorial support, funded by Celgene. There are no patents or marketed products to declare. This paper describes data for a product in clinical development, CC-486. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.","2015","08","Eric Laille","EL",9,TRUE,7,4,4,9,TRUE,TRUE,FALSE,0,NA,FALSE
